Company profile
Agomab Therapeutics NV
NASDAQ:AGMBBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Ontunisertib | phase2 | — | 4 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07118878 | phase1 | completed | 2025-08-06 | 2025-09-15 | Agomab Spain S.L.U. | A Multiple Ascending Dose Study With AGMB-129 in Healthy Participants |
| NCT05937386 | phase1 | completed | 2023-08-09 | 2023-09-06 | Agomab Spain S.L. | Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy Participants |
| NCT07672574 | phase1 | recruiting | 2026-09-09 | 2026-09-26 | Agomab Spain S.L.U. | Human Mass Balance Study of [14C] Ontunisertib in Healthy Volunteers |
| NCT07683325 | phase2 | recruiting | 2026-10-30 | 2028-12-31 | Agomab Spain S.L.U. | NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease |
| NCT06181370 | phase1 | completed | 2023-12-01 | 2026-04-29 | Agomab Spain S.L. | Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF |
FDA applications (0)
No records yet.